Price$0.73-16.95 (-95.86%)
2026-03-042026-06-05
News · 26 weeks45-70%
2025-12-142026-06-07
Mix2790d
- Other13(48%)
- SEC Filings10(37%)
- Insider4(15%)
Latest news
25 items- SECCDT Equity Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CDT Equity Inc. (0001896212) (Filer)
- PRCDT Equity Inc. Announces Receipt of Nasdaq Deficiency LetterNAPLES, Fla. and CAMBRIDGE, United Kingdom, May 28, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced that the Company received a written notice ("Notice") from the Nasdaq Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on May 21, 2026 indicating that the Company did not timely file its Quarterly Report on Form 10-Q for the three-month period ended March 31, 2026 (the "Form 10-Q"), as required for continued listing on The Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5250(c)(1) (the "Periodic Filing Requirement"). The Notice does not have an immediate effect on the listing or trading of the Company's securiti
- PRCDT Announces Canadian Patent for AZD5904 in Male InfertilityNAPLES, Fla. and CAMBRIDGE, United Kingdom, May 27, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announces that the patent covering the use of AZD5904 in male infertility has now been granted in Canada, completing the approval of this patent in all key pharmaceutical target markets. CDT believes that the extensive geographical coverage of this patent combined with its more recent composition of matter application provides a strong IP position for development of AZD5904 in male infertility as discussions continue regarding potential licensing and strategic partnering opportunities. Originally licensed from AstraZeneca, AZD5904 benefits from an exte
- SECSEC Form NT 10-Q filed by CDT Equity Inc.NT 10-Q - CDT Equity Inc. (0001896212) (Filer)
- SECCDT Equity Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits8-K - CDT Equity Inc. (0001896212) (Filer)
- INSIDERChief Executive Officer Regan Andrew was granted 247,401 shares (SEC Form 4)4 - CDT Equity Inc. (0001896212) (Issuer)
- PRCDT Notes Sarborg Filing of Substance of Matter Patent in Cystic Fibrosis MarketNAPLES, Fla. and CAMBRIDGE, United Kingdom, May 07, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today notes the announcement from Sarborg Limited regarding the filing of a new Substance of Matter (SOM) patent covering two established compounds within the cystic fibrosis market. Sarborg announced that the patent was developed using its proprietary Signature Agent and Multi-Agent platform, supported by its Sarborg 1,600 Disease Database and Sarborg 1,700 Rare Disease Database. According to Sarborg, this approach enables rapid identification of new therapeutic opportunities, including additional indications and combination strategies, with patent filing
- PRCDT Advances AZD5904 into Global Patent Phase and Initiates Partnering DiscussionsNAPLES, Fla. and CAMBRIDGE, United Kingdom, May 06, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announces that AZD5904, a potent inhibitor of human Myeloperoxidase, originally licensed from AstraZeneca, has progressed into the Patent Cooperation Treaty ("PCT") phase, marking a significant step in the globalisation of its intellectual property (IP) protection. AZD5904 benefits from an extensive clinical safety data package, with a total of 181 subjects dosed across five Phase 1 studies. The asset has demonstrated a favourable safety profile, with no overtly drug-related adverse events identified. The Company believes this level of human clinical va
- SECSEC Form EFFECT filed by CDT Equity Inc.EFFECT - CDT Equity Inc. (0001896212) (Filer)
- SECSEC Form 424B3 filed by CDT Equity Inc.424B3 - CDT Equity Inc. (0001896212) (Filer)
- INSIDERNew insider Olsen Ulrik K claimed ownership of 233,585 shares (SEC Form 3)3 - CDT Equity Inc. (0001896212) (Issuer)
- SECCDT Equity Inc. filed SEC Form 8-K: Leadership Update8-K - CDT Equity Inc. (0001896212) (Filer)
- SECSEC Form S-3 filed by CDT Equity Inc.S-3 - CDT Equity Inc. (0001896212) (Filer)
- PRCDT Expands Multi-Pathway Value Creation Strategy Across Pharma, IP and AI-Driven DiscoveryNAPLES, Fla. and CAMBRIDGE, United Kingdom, April 16, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today provides a strategic update outlining its positioning as a multi-pathway value creation business spanning a pharmaceutical asset portfolio, proprietary solid-form intellectual property and artificial intelligence-driven indication discovery. The Company believes it is uniquely positioned through a combination of high-quality clinical assets, proprietary chemistry, and advanced data-driven capabilities to generate long-term shareholder value through a capital-efficient, out-licensing model. CDT continues to evaluate and advance its portfolio of asse
- SECSEC Form 10-K filed by CDT Equity Inc.10-K - CDT Equity Inc. (0001896212) (Filer)
- PRCDT Notes Sarborg Publication of PRISM Framework Expanding AINAPLES, Fla. and CAMBRIDGE, United Kingdom, April 07, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today notes the announcement from Sarborg Limited regarding the publication of its research paper titled "PRISM: cross-species connectivity mapping of plant intervention and stress signatures for translational agriculture." CDT holds a 20% equity interest in Sarborg and believes this development represents a meaningful extension of Sarborg's proprietary Signature Intelligence platform beyond its initial pharmaceutical focus into the agrichemical and broader industrial biology sectors. PRISM represents a novel framework for applying connectivity mapping to
- SECSEC Form 424B5 filed by CDT Equity Inc.424B5 - CDT Equity Inc. (0001896212) (Filer)
- SECSEC Form NT 10-K filed by CDT Equity Inc.NT 10-K - CDT Equity Inc. (0001896212) (Filer)
- INSIDERSEC Form 4 filed by Taylor Mark Andrew4 - CDT Equity Inc. (0001896212) (Issuer)
- INSIDERSEC Form 3 filed by new insider Taylor Mark Andrew3 - CDT Equity Inc. (0001896212) (Issuer)
- PRCDT Equity Expands Tapinarof Intellectual Property Portfolio with Two New Patent FilingsNAPLES, Fla. and CAMBRIDGE, United Kingdom, March 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announced the filing of two new patent applications that further expand the Company's intellectual property portfolio surrounding tapinarof, a drug currently approved for the treatment of psoriasis and atopic dermatitis. The first newly filed patent covers a combination therapy pairing tapinarof with a class of drugs clinically proven in psoriasis and atopic dermatitis, while the second patent relates to novel cocrystal forms of tapinarof with these agents. CDT believes these developments may underpin a second-generation tapinarof product with enhance
- SECCDT Equity Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits8-K - CDT Equity Inc. (0001896212) (Filer)
- PRCDT Equity Inc. Announces Reverse Stock SplitNAPLES, Fla. and CAMBRIDGE, United Kingdom, March 25, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company") announces that its board of directors has approved a 1-for-25 reverse stock split of the Company's common stock. The Company's stockholders approved future reverse stock splits, their timing, and granted the board of directors authority to determine future exact split ratios. The reverse stock split will become effective on March 26, 2026, at 5:00 pm, Eastern Time (the "Effective Time"), and the Company's common stock is expected to begin trading on a reverse stock split-adjusted basis on The Nasdaq Capital Market ("Nasdaq") at market open under the existing
- PRCDT Identifies Rare Disease Opportunities Through Sarborg Signature Analysis, Advancing Out-Licensing StrategyNAPLES, Fla. and CAMBRIDGE, United Kingdom, March 23, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (NASDAQ:CDT) ("CDT" or the "Company"), today announces that it has completed initial signature mapping of its asset portfolio against Sarborg Limited's recently curated rare disease database, identifying multiple high-potential opportunities across a range of rare and underserved indications. The analysis, conducted using Sarborg's proprietary AI Signature Agent platform, evaluated CDT's portfolio of assets, including its solid-form patent portfolio and its licensed AstraZeneca compounds AZD1656 and AZD5658, against a database of approximately 1,700 rare disease signatures. The Company reports t
- SECCDT Equity Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - CDT Equity Inc. (0001896212) (Filer)
CDT FAQ
5 questionsWhere does CDT stock trade?
CDT Equity Inc. (CDT) is listed on NASDAQ.What sector and industry is CDT in?
CDT Equity Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did CDT Equity Inc. go public?
CDT Equity Inc. (CDT) completed its IPO in 2022.What companies are similar to CDT?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare CDT side-by-side with any of them on Quantisnow.How can I track CDT on Quantisnow?
Quantisnow aggregates CDT Equity Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CDT to receive live email and push alerts on every new disclosure.